GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:200123335 | Thyroid | ATC | regulation of apoptotic signaling pathway | 206/6293 | 356/18723 | 2.81e-21 | 5.92e-19 | 206 |
GO:000697934 | Thyroid | ATC | response to oxidative stress | 246/6293 | 446/18723 | 2.98e-21 | 6.09e-19 | 246 |
GO:001050632 | Thyroid | ATC | regulation of autophagy | 180/6293 | 317/18723 | 1.34e-17 | 1.46e-15 | 180 |
GO:001056334 | Thyroid | ATC | negative regulation of phosphorus metabolic process | 234/6293 | 442/18723 | 2.30e-17 | 2.31e-15 | 234 |
GO:006219734 | Thyroid | ATC | cellular response to chemical stress | 188/6293 | 337/18723 | 3.16e-17 | 3.07e-15 | 188 |
GO:004593634 | Thyroid | ATC | negative regulation of phosphate metabolic process | 233/6293 | 441/18723 | 3.68e-17 | 3.47e-15 | 233 |
GO:000193333 | Thyroid | ATC | negative regulation of protein phosphorylation | 186/6293 | 342/18723 | 1.43e-15 | 1.08e-13 | 186 |
GO:004232634 | Thyroid | ATC | negative regulation of phosphorylation | 203/6293 | 385/18723 | 5.30e-15 | 3.53e-13 | 203 |
GO:003459934 | Thyroid | ATC | cellular response to oxidative stress | 158/6293 | 288/18723 | 7.35e-14 | 3.94e-12 | 158 |
GO:003134623 | Thyroid | ATC | positive regulation of cell projection organization | 186/6293 | 353/18723 | 7.99e-14 | 4.23e-12 | 186 |
GO:2001234210 | Thyroid | ATC | negative regulation of apoptotic signaling pathway | 129/6293 | 224/18723 | 1.26e-13 | 6.46e-12 | 129 |
GO:000030234 | Thyroid | ATC | response to reactive oxygen species | 128/6293 | 222/18723 | 1.38e-13 | 7.00e-12 | 128 |
GO:004254233 | Thyroid | ATC | response to hydrogen peroxide | 92/6293 | 146/18723 | 3.12e-13 | 1.46e-11 | 92 |
GO:0097191210 | Thyroid | ATC | extrinsic apoptotic signaling pathway | 125/6293 | 219/18723 | 7.19e-13 | 3.16e-11 | 125 |
GO:000150332 | Thyroid | ATC | ossification | 206/6293 | 408/18723 | 9.23e-13 | 3.95e-11 | 206 |
GO:001063926 | Thyroid | ATC | negative regulation of organelle organization | 179/6293 | 348/18723 | 3.74e-12 | 1.50e-10 | 179 |
GO:005105219 | Thyroid | ATC | regulation of DNA metabolic process | 183/6293 | 359/18723 | 5.97e-12 | 2.30e-10 | 183 |
GO:2001236210 | Thyroid | ATC | regulation of extrinsic apoptotic signaling pathway | 89/6293 | 151/18723 | 1.43e-10 | 4.40e-09 | 89 |
GO:004873233 | Thyroid | ATC | gland development | 210/6293 | 436/18723 | 1.50e-10 | 4.59e-09 | 210 |
GO:001097523 | Thyroid | ATC | regulation of neuron projection development | 212/6293 | 445/18723 | 4.16e-10 | 1.14e-08 | 212 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HGF | SNV | Missense_Mutation | rs750282888 | c.401N>A | p.Arg134His | p.R134H | P14210 | protein_coding | tolerated(0.12) | benign(0.215) | TCGA-18-4721-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
HGF | SNV | Missense_Mutation | | c.1130N>T | p.Cys377Phe | p.C377F | P14210 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-21-1070-01 | Lung | lung squamous cell carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
HGF | SNV | Missense_Mutation | novel | c.1851G>T | p.Trp617Cys | p.W617C | P14210 | protein_coding | deleterious(0.02) | probably_damaging(1) | TCGA-21-1083-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
HGF | SNV | Missense_Mutation | | c.407N>G | p.Tyr136Cys | p.Y136C | P14210 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-22-5492-01 | Lung | lung squamous cell carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
HGF | SNV | Missense_Mutation | novel | c.131N>T | p.Lys44Ile | p.K44I | P14210 | protein_coding | deleterious(0) | possibly_damaging(0.646) | TCGA-33-AASD-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
HGF | SNV | Missense_Mutation | novel | c.2110N>T | p.Gly704Cys | p.G704C | P14210 | protein_coding | deleterious(0.01) | possibly_damaging(0.881) | TCGA-39-5040-01 | Lung | lung squamous cell carcinoma | Male | <65 | III/IV | Chemotherapy | cisplatin | PD |
HGF | SNV | Missense_Mutation | | c.416N>A | p.Thr139Lys | p.T139K | P14210 | protein_coding | tolerated(1) | probably_damaging(0.997) | TCGA-56-5897-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
HGF | SNV | Missense_Mutation | novel | c.2123N>T | p.Arg708Leu | p.R708L | P14210 | protein_coding | deleterious(0.02) | probably_damaging(0.996) | TCGA-56-7223-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
HGF | SNV | Missense_Mutation | novel | c.1402N>G | p.Arg468Gly | p.R468G | P14210 | protein_coding | tolerated(0.11) | possibly_damaging(0.454) | TCGA-56-A4BX-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | chemo | CR |
HGF | SNV | Missense_Mutation | novel | c.1774G>C | p.Asp592His | p.D592H | P14210 | protein_coding | deleterious(0.02) | benign(0.271) | TCGA-58-A46K-01 | Lung | lung squamous cell carcinoma | Male | <65 | III/IV | Chemotherapy | carboplatin | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3082 | HGF | PROTEASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, GROWTH FACTOR, KINASE, ENZYME | | STI571 | IMATINIB MESYLATE | 11439348 |
3082 | HGF | PROTEASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, GROWTH FACTOR, KINASE, ENZYME | | THALIDOMIDE | THALIDOMIDE | 15939924 |
3082 | HGF | PROTEASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, GROWTH FACTOR, KINASE, ENZYME | | ASPIRIN | ASPIRIN | 11981761 |
3082 | HGF | PROTEASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, GROWTH FACTOR, KINASE, ENZYME | | VM-202 | | |
3082 | HGF | PROTEASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, GROWTH FACTOR, KINASE, ENZYME | | Ficlatuzumab | FICLATUZUMAB | |
3082 | HGF | PROTEASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, GROWTH FACTOR, KINASE, ENZYME | | PROTEOLYTIC ENZYMES | | 9502079 |
3082 | HGF | PROTEASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, GROWTH FACTOR, KINASE, ENZYME | antibody | RILOTUMUMAB | RILOTUMUMAB | |
3082 | HGF | PROTEASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, GROWTH FACTOR, KINASE, ENZYME | | RESVERATROL | RESVERATROL | 15672869 |
3082 | HGF | PROTEASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, GROWTH FACTOR, KINASE, ENZYME | | TAK-701 | | |
3082 | HGF | PROTEASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, GROWTH FACTOR, KINASE, ENZYME | | FICLATUZUMAB | FICLATUZUMAB | |